Chantix, Zyban Safety Issues Put Focus On REMS Assessment Efforts
Executive Summary
GlaxoSmithKline is writing a questionnaire to ascertain whether patients receiving the firm's smoking cessation drug Zyban understand the risk of potential neuropsychiatric side effects
You may also be interested in...
Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M
The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.
Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M
The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.
FDA Diabetes Guidance Encourages Enrollment Of Sicker Patients
In raising pre-market safety standards, FDA says that development time will not necessarily increase if a robust protocol is used.